Clinical Trial Update: 68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC

View source ↗

Summary

This clinical trial evaluates the radiotracer 68Ga-grazytracer PET/CT for early assessment of response to neoadjuvant immunotherapy in resectable non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• 68Ga-grazytracer

Snippet

Sponsor: Ruijin Hospital | Conditions: Non-Small Cell Lung Cancer | Status: RECRUITING